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Wiskott Aldrich syndrome (WAS) is an X-linked disease, which is caused by mutations in 
the gene encoding the WAS protein (WASp). WASp expression is restricted to the 
hematopoietic cell lineages and plays significant role in a variety of hematopoietic cells 
such as T cells, B cells, dendritic cells, monocytes and Platelets regarding their 
development and function. This disease is characterized by thrombocytopenia, 
immunodeficiency and eczema. As thrombocytopenia (Platelet count of below 150 x 109 
per liter) is the most typical feature of this disease, often exposing patients to a significant 
risk of life-threatening hemorrhage, it has been the main subject of study for many 
researchers. Based on the severity of symptoms of patients, they categories into 5 groups. 
The milder phenotype of the disease is called XLT and the sever type is named WAS. Mice 
models does not phenocopy the disease features properly as they appear to have almost 
normal platelet count. Because of limitations in disease modeling, precise mechanisms of 
the platelet abnormality remain to be elucidated. Recently, human pluripotent stem cell 
(including human embryonic stem cells [hESC] and induced pluripotent stem cell [iPSC]) 
have gave a unique opportunity to the scientist to work on understanding the 
pathophysiology of genetic diseases. iPSCs are patient-derived cells which harbor the 
patient cell’s defects and provide us infinitely proliferation in vitro, therefor they can be 
used as a useful model providing important information about microthrombocytopenia in 
WAS/XLT patients.  Here we established induced pluripotent stem cell (iPSC) lines from 
CD34+ cells of peripheral blood by utilizing Sendai virus harboring four Yamanaka factors 
(SOX2, KLF4, OCT3/4 and c-MYC) from two XLT and one WAS patients (each harboring 
different mutations) as disease models to address the issues. Characterization of iPSC lines 
revealed that iPSC clones retained typical characterization of pluripotent stem cells. We 
then confirmed that these disease-specific iPSCs retained gene mutations characteristic to 
each patient. Further we used this iPSCs to produce megakaryocyte and platelet upon 
differentiation to hematopoietic lineages. In brief, iPSCs were co-cultured with C3H10T1/2 
cells in the presence of 20 ng/ml VEGF to generate hematopoietic progenitor cells. The 
progenitor cells fraction which were double positive for CD34 and CD41 were sorted using 
FACS analysis and further cultured for 9 more days in the presence of a cytokine cocktail 
including 100 ng/ml TPO and 50 ng/ml SCF to produce mature megakaryocytes and 
platelets. Using our differentiation culture system, we demonstrated that numbers of both 
megakaryocytes (MK)s and platelets (PLT)s - showing double positive CD41 and CD42 
cell surface markers- obtainable from the same number of hematopoietic progenitor cells 
are significantly smaller in both XLT- and WAS-iPSCs comparing to those from healthy- 
iPSCs. In addition we demonstrated that the number of proplatelet bearing cells obtained 
from same numbers of progenitor cells is significantly reduced in patient samples 
comparing to the healthy counterpart. Estimation of platelet numbers released by each 
megakaryocytes showed that both patient-iPSCs and healthy-iPSCs generate comparable 
numbers of platelets and platelet production ability of megakaryocytes is not affected by 
WASp deficiency. Hence, we suggested that the observed defects in platelet number of 
patient samples were mainly due to insufficient production of proplatelet-bearing cells, but 
not to impaired platelet production per MK. Previous studies have suggested that WASp has 
important role in hematopoietic cell proliferation and differentiation. We assessed colony 
formation ability of both XLT- and WAS-iPSCs using MethoCult H4434 semisolid medium 
differentiation kit. In this assay hematopoietic progenitor cells (HPC; CD 41- , CD 235- , 
CD 34+, CD 43+, CD 45+) obtained from SAC structure in the day 14 of iPSC 
differentiation were used. Interestingly our data revealed that the ability of patient-HPCs 
for differentiation to the hematopoietic lineage is affected by WASp deficiency and it varies 
between patient samples and depends on the distinct type of mutation. Later we sought for a 
possible role of WASp in the cytokine mediated cell signaling in the process of 
differentiation of progenitor cells to megakaryocytes. We analyzed phosphorylation of 
downstream molecules of TPO receptor (MPL) as TPO is the main applied cytokine which 
is essential for megakaryocyte differentiation. At first we tested the expression level of 
MPL using FACS and could not detect any significant different between healthy samples 
and patient samples. Based on the FACS analysis data we suggest that WASp in involved in 
TPO signaling pathway since a dull phosphorylation of downstream molecules of MPL  
was seen for WASp null progenitor cells (CD34+ )comparing to healthy counterpart  upon 
stimulation with 100 ng/ml TPO for 10 minutes. Lentiviral-mediated gene transfer led to 
appearance of WASp expression in patient iPSC-derived MKs. Although the expression 
level of WASp did not reach the normal level that was seen in control-iPSC-MKs; it 
seemed to be sufficient to significantly increase yields of platelets and megakaryocytes 
comparing to the control vector after gene transfer. The low expression level of WASp after 
gene therapy comparing to the physiological expression of the protein in healthy sample 
maybe the reason which we could not get as high number of platelets as healthy samples 
after gene addition. This may suggest the necessity of a distinct expression pattern and level 
of WASp in CD34+ progenitor cells for complete reconstitution of platelet number. The low 
expression level of WASp in megakaryocytes after gene transfer may be consistent with a 
recently published clinical trial’s data reporting dull expression level of WASp in the 
platelets after gene therapy while other hematopoietic cells such as T cells expressed almost 
normal level of WASp. 
 In conclusion our data propose that reduced number of platelet which was observed in both 
XLT and WAS patients is due to lessen proplatelet bearing cells and WASp deficiency does 
not interrupt the ability of each megakaryocytes to shed platelets and besides, less numbers 
of proplatelet bearing cells is attributed by defective TPO signaling pathway in WASp 
deficient progenitor cells.  Although further investigation is necessary, these results indicate 
the utility of iPSC-based disease modeling for WAS. More detailed analysis is required to 
understand the mechanism underlying insufficient WASp expression in megakaryocytes 
after gene transfer and consequently discern how critically expression levels of WASp will 
affect the efficacy in platelet number recovery after gene transfer. 
 
